A5042481304- Prostate Cancer Treatment and Research
- Renal cell carcinoma treatment
- Prostate Cancer Diagnosis and Treatment
- Epigenetics and DNA Methylation
- Phagocytosis and Immune Regulation
- Renal and related cancers
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Radiopharmaceutical Chemistry and Applications
- Urologic and reproductive health conditions
- Cancer, Lipids, and Metabolism
- Ferroptosis and cancer prognosis
- Bladder and Urothelial Cancer Treatments
- Pancreatic and Hepatic Oncology Research
- Pelvic floor disorders treatments
- Cancer-related molecular mechanisms research
- PARP inhibition in cancer therapy
- Hormonal and reproductive studies
- Multiple and Secondary Primary Cancers
- Economic and Financial Impacts of Cancer
- Genetic factors in colorectal cancer
- Advanced Radiotherapy Techniques
- Colorectal Cancer Surgical Treatments
- Radiomics and Machine Learning in Medical Imaging
- Aldose Reductase and Taurine
Sichuan University
2017-2025
West China Hospital of Sichuan University
2017-2025
Affiliated Zhongshan Hospital of Dalian University
2025
Creative Commons
2023
Southern Medical University
2022
Nanfang Hospital
2022
Chengdu University
2019
Weatherford College
2019
Weihai Maternal and Child Health Hospital
2016
Qingdao University
2014
Abstract TFE3 -translocation renal cell carcinoma ( -tRCC) is a rare and heterogeneous subtype of kidney cancer with no standard treatment for advanced disease. We describe comprehensive molecular characteristics 63 untreated primary -tRCCs based on whole-exome RNA sequencing. -tRCC highly heterogeneous, both clinicopathologically genotypically. ASPSCR1-TFE3 fusion several somatic copy number alterations, including the loss 22q, are associated aggressive features poor outcomes. Apart from...
Abstract Purpose: Fumarate hydratase–deficient renal cell carcinoma (FH-deficient RCC) is a rare but lethal subtype of RCC. Little known about the genomic profile FH-deficient RCC, and therapeutic options for advanced disease are limited. To this end, we performed comprehensive genomics study to characterize epigenomic features Experimental Design: Integrated genomic, epigenomic, molecular analyses were on 25 untreated primary RCCs. Complete clinicopathologic follow-up data these patients...
Fumarate hydratase-deficient renal cell carcinoma (FH-deficient RCC) is a rare yet highly lethal kidney cancer. To deepen our understanding of FH-deficient RCC, we conduct comprehensive integrated genomic study. We analyze the association FH alteration patterns with tumor heterogeneity and develop CpG site-specific methylation signature for precise identification RCC. Transcriptomic analysis unveils three distinctive molecular subtypes characterized by enrichment immune/Angiogenic/Stromal...
To evaluate whether local injection of exosomes derived from human adipose-derived stem cells (hADSCs) facilitates recovery stress urinary incontinence (SUI) in a rat model.For the vitro study, Cell Counting Kit-8 (CCK-8) array and proteomic analysis were performed. For vivo female rats divided into four groups: sham, SUI, cell (ADSC), (n = 12 each). The SUI model was generated by pudendal nerve transection vaginal dilation. Vehicle, hADSCs, or injected peripheral urethra. After 2, 4, 8...
In clinical practice, the detection of biomarkers is mostly based on primary tumors for its convenience in acquisition. However, immune checkpoints may express differently between and metastatic tumor. Therefore, we aimed to compare differential expressions PD-1, PD-L1 PD-L2 sites renal cell carcinoma (RCC).Patients diagnosed with RCC by resection or fine needle aspiration metastasis were included. Immunohistochemistry (IHC) was applied detect expressions. SPSS 22.0 conduct Chi-square,...
Abstract Background Intraductal carcinoma of the prostate (IDC-P) is a subtype cancer featured by poor prognosis. Previous studies suggested IDC-P could have potentially unstable genome. Homologous recombination deficiency (HRD) score result-oriented method to describe genomic instability status. This study investigates association HRD scores with and other clinicopathological factors prognostic implication in an aggressive cohort. Methods involved 123 PCa patients, including high-risk...
Fumarate hydratase-deficient renal cell carcinoma (FH-RCC) is a rare highly aggressive subtype of kidney cancer for which the distinct genomic, transcriptomic, and evolutionary relationships between metastatic primary lesions are still unclear.
Multidisciplinary team (MDT) discussion is a widely used model to manage patients diagnosed with cancer. However, there has been no direct evidence prove its effect on the prognosis of metastatic renal cell carcinoma (mRCC) patients, so this study explored impact MDT mRCC patient survival.The clinical data 269 were retrospectively collected from 2012 2021. The cases grouped into and non-MDT groups, then subgroup analysis was performed according different histology types, as well exploring...
Objectives To investigate the genetic alterations of patients with prostate cancer (PCa) and without intraductal carcinoma (IDC‐P). Patients Methods We performed targeted sequencing plasma cell‐free DNA on 161 adenocarcinoma (PAC) IDC‐P 84 IDC‐P. Genomic were compared between these two groups. The association patients’ survival outcomes was also explored. Results identified that 29.8% (48/161) 21.4% (18/84) harboured genomic in repair pathways, respectively ( P = 0.210). Pathogenic germline...
544 Background: Non-clear cell renal carcinoma (nccRCC) accounts for approximately 25% of all (RCC) and lacks standards care. More recent data suggests the efficacy anti-PD-(L)1 plus anti-CTLA-4 immune checkpoint inhibitors combined with tyrosine-kinase in RCC. Cadonilimab (AK104) is a first-in-class tetravalent bispecific antibody that targets both PD-1 CTLA-4, showing manageable safety profile favorable clinical benefits. Here we explore cadonilimab combination axitinib patients advanced...
TPS616 Background: Despite substantial advances in therapy over the past 20 years, median progression-free survival (mPFS) for advanced RCC patients treated with first-line tyrosine kinase inhibitors (TKIs) and immune checkpoint (ICIs) remains around months (Motzer RJ et al., NEJM 2021, Choueiri TK 2021). Moreover, subsequent treatments post-first-line progression exhibit inadequate efficacy. A phase Ib/II single-arm trial achieved a high objective response rate (ORR) lenvatinib plus...
ABSTRACT Background The prognostic value of the prostate adenocarcinoma (PAC) with ductal feature in patients advanced cancer treated abiraterone acetate has not been scrutinized. This study aims to explore predictive PAC on therapeutic efficacy therapy metastatic (mPCa) patients. Methods We retrospectively analyzed data from 569 mPCa receiving at either hormone‐sensitive (mHSPC, N = 165) or castration‐resistant (mCRPC, 404) stage. PSM was performed balance baseline characteristics between...
Abstract Background Previous studies had demonstrated that aldo‐keto reductase family 1 member C3 (AKR1C3), a crucial enzyme in the steroidogenic pathway, played an important role abiraterone (ABI)‐resistance metastatic castration‐resistant prostate cancer (mCRPC) by increasing intratumoral androgen synthesis. However, its value predicting treatment response patients with mCRPC is unknown. Method and Materials Data of 163 between 2016 2018 were retrospectively analyzed. All received...
Pelvic lymph node dissection (PLND) represents the gold standard for nodal staging in PCa and is recommended patients with a probability of invasion (LNI) >5%. However, therapeutic role PLND its extent remains debate. In this study, data 20,668 treated radical prostatectomy (RP) without from SEER database between 2010 2015 were retrospectively analyzed. All had risk LNI >5% according to 2012-Briganti nomogram. Propensity score matching (PSM) was performed balance baseline characteristics...
Multidisciplinary team (MDT) management is a popular treatment paradigm in managing cancer patients, which provides fully-discussed, interdisciplinary recommendations for patients. However, there has been lack of data on its actual impact the overall survival (OS) metastatic castration-resistant prostate (mCRPC) mCRPC end stage cancer, facing dilemma overwhelming options; therefore, we hypothesize dynamic MDT discussions can be helpful comprehensively these patients.We retrospectively...
Abstract Intraductal carcinoma of the prostate (IDC-P) is a lethal cancer subtype that generally coexists with invasive high-grade acinar adenocarcinoma (PAC) but exhibits distinct biological features compared concomitant adenocarcinoma. In this study, we performed whole-exome, RNA, and DNA-methylation sequencing IDC-P, concurrent PAC lesions, adjacent normal tissues isolated from 22 radical prostatectomy specimens. Three evolutionary patterns IDC-P were identified: early divergent, late...